Ishara Investments LP Makes New $2.34 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Ishara Investments LP purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 300,000 shares of the biotechnology company’s stock, valued at approximately $2,340,000. BioCryst Pharmaceuticals comprises 2.7% of Ishara Investments LP’s holdings, making the stock its 11th biggest holding.

A number of other hedge funds have also modified their holdings of the stock. Phocas Financial Corp. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $1,956,000. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 6.1% during the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock worth $165,393,000 after purchasing an additional 1,246,633 shares during the period. Aberdeen Group plc acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $7,126,000. Public Sector Pension Investment Board acquired a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth $2,010,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in shares of BioCryst Pharmaceuticals by 106.5% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock worth $1,820,000 after purchasing an additional 120,350 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Up 0.3%

BioCryst Pharmaceuticals stock opened at $8.95 on Thursday. The company’s fifty day simple moving average is $8.92 and its 200-day simple moving average is $8.16. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $10.32. The stock has a market cap of $2.27 billion, a P/E ratio of -5.03 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. During the same quarter in the prior year, the firm earned $0.20 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. On average, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BCRX. Citizens Jmp boosted their target price on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Needham & Company LLC lowered their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Evercore started coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective on the stock. Finally, Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.